OmniaBio has announced the opening of a new North American cell and gene therapy manufacturing and AI center of excellence, which will become Canada’s largest CDMO facility dedicated to CGT.
The 120,000-square-foot commercial-ready facility is located at McMaster Innovation Park in Hamilton, Ontario — close proximity to the U.S. border and Canada’s largest international airport. The facility will offer critical cold chain logistics, dedicated staff training infrastructure, intelligently designed production flows, and a multi-modality layout facilitating both cell and vector-focused manufacturing. It will employ advanced technologies such as robotics, biosensors and machine learning.
According to OmniaBio, its AI-enabled manufacturing will first focus on cellular immunotherapies and iPSC-based therapies.
OmniaBio was founded in 2022 by Canada’s Centre for Commercialization of Regenerative Medicine (CCRM), a public-private partnership. It was the first project to be funded under the Invest Ontario Fund, receiving a $40 million loan from the government of Ontario. OmniaBio later formed a partnership with Korean biotech, Medipost.